JP2021013322A - 光活性化アデニル酸シクラーゼ - Google Patents
光活性化アデニル酸シクラーゼ Download PDFInfo
- Publication number
- JP2021013322A JP2021013322A JP2019129374A JP2019129374A JP2021013322A JP 2021013322 A JP2021013322 A JP 2021013322A JP 2019129374 A JP2019129374 A JP 2019129374A JP 2019129374 A JP2019129374 A JP 2019129374A JP 2021013322 A JP2021013322 A JP 2021013322A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- protein
- photoactivated
- oapac
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000030621 adenylate cyclase Human genes 0.000 title claims abstract description 35
- 108060000200 adenylate cyclase Proteins 0.000 title claims abstract description 35
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 80
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 48
- 230000000694 effects Effects 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 230000002186 photoactivation Effects 0.000 abstract description 33
- 235000018102 proteins Nutrition 0.000 description 74
- 150000001413 amino acids Chemical class 0.000 description 38
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000195619 Euglena gracilis Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 241000190909 Beggiatoa Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000192497 Oscillatoria Species 0.000 description 2
- 241000248493 Oscillatoria acuminata Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000004475 Arginine Chemical group 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100177112 Caenorhabditis elegans his-70 gene Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091000182 THR-184 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 101150111388 pac gene Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Chemical group 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
[1]光活性化アデニル酸シクラーゼ活性を有するタンパク質であって、1〜18のアミノ酸残基がC末端から欠失された配列番号1のアミノ酸配列、又はこれと90%以上の配列同一性を有するアミノ酸配列からなる、タンパク質。
[2]配列番号1のアミノ酸配列のC末端から欠失されたアミノ酸残基の数が5〜7である、上記[1]に記載のタンパク質。
[3]上記[1]又は[2]に記載のタンパク質をコードする、核酸。
[4]上記[3]に記載の核酸を含む、ベクター。
[5]上記[4]に記載のベクターが導入された、形質転換体。
[6]上記[5]に記載の形質転換体を培養することを含む、上記[1]又は[2]に記載のタンパク質の製造方法。
[7]1〜18のアミノ酸残基を光活性化アデニル酸シクラーゼのC末端から欠失させることを含み、上記光活性化アデニル酸シクラーゼはユレモ属に由来する、アデニル酸シクラーゼの光活性化効率を向上させる方法。
哺乳類に最適化されたコドンを有するOaPAC遺伝子(Oa−366遺伝子;配列番号8)を合成した。また、一般的な遺伝子組み換え技術を利用してOa−366の塩基配列から特定のヌクレオチドを欠失させ、変異型OaPAC遺伝子であるOa−363、Oa−360、Oa−357、Oa−354、Oa−351及びOa−348を得た。欠失させたヌクレオチドの位置を表2に示す。
GloSensor(商標)−22F cAMP遺伝子(プロメガ株式会社)を哺乳類発現ベクターpEBMulti−Neo(富士フイルム和光純薬株式会社)に組み込んだ。得られたpEBMulti−Neo−GloSensor−22F cAMPプラスミドを、FuGENE(登録商標) HD(プロメガ株式会社)を用いたリポフェクションによりヒト胎児腎臓細胞HEK293(株式会社ケー・エー・シー)に導入し、GloSensor−22F cAMPを安定的に発現する細胞株を樹立した。
OaPAC発現コンストラクトのそれぞれを、Ingenio(登録商標)Electroporation kit with 0.4cmcuvettes(マイラス・バイオ社)及びGene Pulserエレクトロポレーションシステム(バイオ・ラッド ラボラトリーズ株式会社、印加条件:260V,950μF)を用いた電気穿孔法によりGloSensor−22F cAMP発現HEK293に導入し、野生型又は変異型のOaPACタンパク質とGloSensor−22F cAMPタンパク質とを発現するHEK293を得た。なお、2A−ペプチドの働きによりOaPACタンパク質の発現の度合いはRFPタンパク質の発現の度合いと等しいため、OaPACタンパク質の発現の度合いは、RFPの蛍光強度により確認した。
OaPAC発現HEK293を、35mm培養皿(BioCoat(商標)コラーゲンI、コーニング社)に播種し、2mLの培地(DMEM high glucose with 10%FBS and 4mM L−glutamine、サーモフィッシャー・サイエンティフィック社)で培養した。細胞に光を照射する数時間前に培地をCO2非依存性培地(サーモフィッシャー・サイエンティフィック社)に交換し、終濃度0.12mg/mLでGloSensor cAMP Reagent(プロメガ株式会社)を添加した。数時間後、EM−CCDカメラ(ImagEM C9100−23B、浜松ホトニクス株式会社)及び青色LED(LXML−PR01−0425、ルクシオン・レベル、フィリップス・ルミレッズ社)を取り付けた倒立蛍光顕微鏡(Eclipse TE−300、株式会社ニコン)を用いて、暗室にて以下の照射実験を行った。
Claims (5)
- 光活性化アデニル酸シクラーゼ活性を有するタンパク質であって、
1〜18のアミノ酸残基がC末端から欠失された配列番号1のアミノ酸配列、又はこれと90%以上の配列同一性を有するアミノ酸配列からなる、タンパク質。 - 配列番号1のアミノ酸配列のC末端から欠失されたアミノ酸残基の数が5〜7である、請求項1に記載のタンパク質。
- 請求項1又は2に記載のタンパク質をコードする、核酸。
- 請求項3に記載の核酸を含む、ベクター。
- 請求項4に記載のベクターが導入された、形質転換体。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019129374A JP7340372B2 (ja) | 2019-07-11 | 2019-07-11 | 光活性化アデニル酸シクラーゼ |
PCT/JP2020/016461 WO2021005862A1 (ja) | 2019-07-11 | 2020-04-14 | 光活性化アデニル酸シクラーゼ |
US17/624,373 US20220356460A1 (en) | 2019-07-11 | 2020-04-14 | Photoactivated adenylyl cyclase |
CN202080028220.9A CN114040968A (zh) | 2019-07-11 | 2020-04-14 | 光活化腺苷酸环化酶 |
EP20837089.0A EP3998334A4 (en) | 2019-07-11 | 2020-04-14 | LIGHT-ACTIVATED ADENYLATCYCLASE |
TW109115350A TW202117010A (zh) | 2019-07-11 | 2020-05-08 | 光活化腺苷酸環化酶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019129374A JP7340372B2 (ja) | 2019-07-11 | 2019-07-11 | 光活性化アデニル酸シクラーゼ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021013322A true JP2021013322A (ja) | 2021-02-12 |
JP7340372B2 JP7340372B2 (ja) | 2023-09-07 |
Family
ID=74113953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019129374A Active JP7340372B2 (ja) | 2019-07-11 | 2019-07-11 | 光活性化アデニル酸シクラーゼ |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220356460A1 (ja) |
EP (1) | EP3998334A4 (ja) |
JP (1) | JP7340372B2 (ja) |
CN (1) | CN114040968A (ja) |
TW (1) | TW202117010A (ja) |
WO (1) | WO2021005862A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017007949A (ja) * | 2015-06-16 | 2017-01-12 | 国立大学法人滋賀医科大学 | 高血圧症の予防又は治療用医薬 |
WO2018140456A1 (en) * | 2017-01-24 | 2018-08-02 | Northwestern University | Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) |
WO2019071048A1 (en) * | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
-
2019
- 2019-07-11 JP JP2019129374A patent/JP7340372B2/ja active Active
-
2020
- 2020-04-14 US US17/624,373 patent/US20220356460A1/en active Pending
- 2020-04-14 EP EP20837089.0A patent/EP3998334A4/en active Pending
- 2020-04-14 CN CN202080028220.9A patent/CN114040968A/zh active Pending
- 2020-04-14 WO PCT/JP2020/016461 patent/WO2021005862A1/ja unknown
- 2020-05-08 TW TW109115350A patent/TW202117010A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017007949A (ja) * | 2015-06-16 | 2017-01-12 | 国立大学法人滋賀医科大学 | 高血圧症の予防又は治療用医薬 |
WO2018140456A1 (en) * | 2017-01-24 | 2018-08-02 | Northwestern University | Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) |
WO2019071048A1 (en) * | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION |
Non-Patent Citations (3)
Title |
---|
"Accession No.YP_007087096", DATABASE GENBANK [ONLINE], JPN6023014933, 2014, ISSN: 0005038278 * |
CRASNIER, M. ET AL., MOL GEN GENET, vol. 243, JPN6020023498, 1994, pages 409 - 416, ISSN: 0005038279 * |
OHKI, M. ET AL., PROC. NATL. ACAD. SCI., vol. 113, JPN6023014932, 2016, pages 6659 - 6664, ISSN: 0005038277 * |
Also Published As
Publication number | Publication date |
---|---|
EP3998334A1 (en) | 2022-05-18 |
US20220356460A1 (en) | 2022-11-10 |
EP3998334A4 (en) | 2023-07-12 |
TW202117010A (zh) | 2021-05-01 |
CN114040968A (zh) | 2022-02-11 |
JP7340372B2 (ja) | 2023-09-07 |
WO2021005862A1 (ja) | 2021-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6294368B2 (ja) | 直交tRNA−アミノアシルtRNAシンテターゼ対を生産するための方法及び組成物 | |
US9115184B2 (en) | Light-inducible system for regulating protein stability | |
KR20180132786A (ko) | 피브로인형 단백질 개변체 및 세포 배양 방법 | |
CN110373404B (zh) | 一种酶突变体 | |
Yu et al. | Rational design of a monomeric and photostable far‐red fluorescent protein for fluorescence imaging in vivo | |
KR101544650B1 (ko) | 광합성 산물의 생산성을 향상시킨 조류 및 그의 이용 | |
JP2008522589A (ja) | 組換えタンパク質の発現のための方法及び材料 | |
CN106244608B (zh) | 诱导的t7 rna聚合酶 | |
WO2021005862A1 (ja) | 光活性化アデニル酸シクラーゼ | |
EP3953470A1 (en) | Compositions and methods for improved gene editing | |
WO2008094316A2 (en) | Novel branchiostoma derived fluorescent proteins | |
KR101833896B1 (ko) | 플라빈 기반 형광 단백질 변이체 | |
KR102198460B1 (ko) | 생물 발광 유도용 재조합 플라스미드 | |
JP7241358B2 (ja) | 細胞移植用組成物及び細胞移植方法 | |
JP2014161229A (ja) | タンパク質の発現を制御する方法 | |
KR102341951B1 (ko) | 형광세기가 증진된 적색형광단백질 변이체 | |
CA2830805A1 (fr) | Constructions et procede pour reguler l'expression des genes ou pour detecter et controler un locus d'adn chez les eucaryotes | |
EP3988562A1 (en) | Flavin mononucleotide-binding protein variants having improved fluorescence intensity derived from arabidopsis thaliana | |
CN113336854B (zh) | 一种精氨酸荧光探针及其制备方法和应用 | |
WO2024029527A1 (ja) | 長波長の光照射で機能する光スイッチタンパク質 | |
TWI725593B (zh) | 光遺傳學控制下的遺傳編碼螢光指示劑 | |
WO2022261075A1 (en) | Photoactivatable gasdermin proteins | |
EP3505625B1 (en) | Modified luciferase | |
Karki | Programmed Translational Readthrough in Drosophila melanogaster | |
WO2020045651A1 (ja) | 光活性化可能なTet発現制御システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230607 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230726 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230726 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230822 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230828 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7340372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |